Last reviewed · How we verify
Accroibile (CICROTOIC ACID)
Accroibile (generic name: CICROTOIC ACID) is a cicrotoic acid drug. It is currently in Phase 2 development.
Cicrotoic acid is thought to work by interacting with a specific molecular target to produce its therapeutic effect.
Cicrotoic acid is a small molecule drug of the cicrotoic acid class, but its details are limited. Its original developer and current owner are unknown. The target and approved indications of cicrotoic acid are also not specified. Its commercial status, including patent status and generic availability, is unclear. Further research is needed to understand its pharmacokinetics and safety profile.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CICROTOIC ACID |
|---|---|
| Drug class | cicrotoic acid |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells have locks on them, and cicrotoic acid has a key that fits into those locks. When it binds to the lock, it triggers a series of events that help to treat the condition it's intended for. This is a simplified explanation of how cicrotoic acid is thought to work at a molecular level.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Accroibile CI brief — competitive landscape report
- Accroibile updates RSS · CI watch RSS
Frequently asked questions about Accroibile
What is Accroibile?
How does Accroibile work?
What is the generic name of Accroibile?
What drug class is Accroibile in?
What development phase is Accroibile in?
Related
- Drug class: All cicrotoic acid drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing